Abstract: A joint application process of two treatments, scale removal and inhibitor squeeze injection, is described herein. Through the simultaneous positioning inside the reservoir, it can be applied in scale removal operations for carbonate formations, such as the pre-salt case. Accordingly, there is a way to improve the efficiency of reservoir management, through an innovation in the scaling management process.

Abstract: The present invention relates to an extract of Bertholletia excelsa seeds obtained from extracting an at least partly deoiled press residue of Bertholletia excelsa seeds and to a method for preparing such extract. Furthermore, the present invention refers to a cosmetic or pharmaceutic composition comprising such extract as active ingredient and to the use of the extract or the composition for skin care.

Abstract: The invention discloses a soybean plant, or a part of said plant comprising the transgenic event CIGBDt-Def1 or the transgenic event CIGBIs-Def5, as well as a method for the detection of those events in soybean samples. It also provides a seed from a soybean plant comprising said transgenic events, and products obtained from a plant, or from soybean seeds, comprising one of said events. In addition, the invention is related to a method for the production of soybean plants resistant to glyphosate, and to diseases caused by fungi or oomycetes, comprising the introduction of one of the mentioned transgenic events in the genome of said plants. The increase in the yield of a soybean crop in the field can be achieved with the transgenic events of the invention.

Abstract: Therapeutic Agents, Pharmaceutical Compositions, and Associated Biomarkers The invention relates to the identification of pharmaceutical compositions, therapeutic agents, peptides, nucleic acids, genetic constructs, vectors, cells, and medicaments, and their use in methods of treatment. For example, the treatment of neuropathological conditions, in particular Alzheimer's disease. Furthermore, provided herein are biomarkers, methods for their use, methods of diagnosis, methods of monitoring disease progression, and methods for monitoring medicament efficacy, in particular for Alzheimer's disease.

Abstract: The present invention relates to the use of a combination of a phosphodiesterase 4 (PDE4) inhibitor and one or more of 5-HT4 agonist, an H3 antagonist or inverse agonist, a nicotinic ?7 receptor agonist, a ?3 adrenergic agonist or a TAAR1 agonist for the treatment of psychiatric or neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction exists (such as major depressive disorder, bipolar I disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative and cognitive symptoms), as well as Parkinson's disease (e.g. non-motor features such as depression, apathy and cognitive impairment)).

Abstract: The present disclosure relates to nitenin analogue compounds (of formulas I, II, III and IV) and their use as pharmaceutical agent in the treatment, prevention or reduction of both acute and chronic pain. The mode of action disclosed herein allows nitenin and nitenin analogue compounds to act as analgesic through reduction of K30 currents rather than their potentiation. Related to their high efficacy in the treatment of pain, these compounds are highly selective for slow voltage-activated potassium (K30 ) currents expressed in the small diameter dorsal root neurons (sDRGns), mainly on those mediated by the voltage-dependent potassium channel (KV), KV1.3. Such findings, together with those showing that nitenin and nitenin analogue compounds act as activity dependent blockers also lead to very reduced side-effects.

Abstract: The present patent application relates to the use of antagonists of delayed rectifier potassium (K+) channels, more specifically Kv1.3 antagonists, as pharmaceutical agents in the treatment, prevention or reduction of both acute and chronic pain. The results and mode of action disclosed herein describe how Kv1.3 antagonists may act as analgesics through reduction of K+ currents rather than their potentiation. With regard to their high efficacy in the treatment of pain, these compounds are highly selective for slow delayed rectifier voltage-activated potassium (K+) currents. Such findings, together with those showing that nitenin, PSORA-4, PAP-1 and AM92016 hydrochloride act as K+ channel blockers and by their effects on K+ current inactivation profiles, also translate into an analgesic effect with reduced side effects. The results disclosed herein show that compounds that inhibit delayed rectifying Kv1.

Abstract: The present invention relates to the use of a combination of a phosphodiesterase 4 (PDE4) inhibitor and one or more of 5-HT4 agonist, an H3 antagonist or inverse agonist, a nicotinic ?7 receptor agonist, a ?3 adrenergic agonist or a TAAR1 agonist for the treatment of psychiatric or neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction exists (such as major depressive disorder, bipolar I disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative and cognitive symptoms), as well as Parkinson's disease (e.g. non-motor features such as depression, apathy and cognitive impairment)).

Abstract: The present invention relates generally to electronic smoking devices and in particular electronic cigarettes. A mouthpiece for an electronic smoking device has an elongated housing having ports at opposite ends; a central passage formed as a hollow channel through the housing in communication with the ports, contact terminals for connecting to a battery of the electronic smoking device and conductive elements connected to the contact terminals, the conductive elements being configured for connecting, to the battery, an tempering element for tempering an aerosol produced by the electronic smoking device. Using the tempering element, aerosol passing through the central passage can be tempered and loss of aerosol due to condensation is reduced.

Abstract: A method of determining the effectiveness of a therapist, comprising: obtaining data relating to one or more patient variables and/or one or more service variables for one or more patient suffering from a mental health disorder and allocated to the therapist; attributing a score to the data for each of the patient variables and/or the service variables, wherein the scores are based on a correlation between historic cohort treatment outcomes and historic cohort data comprising cohort patient and/or service variables; combining the scores to calculate an aggregate score; comparing the aggregate score with a scale to produce a prediction of psychological therapy outcome for the one or more patient; obtaining an observation of psychological therapy outcome for the one or more patient after treatment by the therapist has been provided; and comparing the observation of psychological therapy outcome and the prediction of psychological therapy outcome for the one or more patient to make a determination of the effecti

Abstract: A computer-implemented method of assigning a treatment protocol to a patient, comprising the steps of: obtaining a plurality of patient profile data points relating to the patient at an initial stage of a psychotherapy process; comparing each patient profile data point with the corresponding data point for each one of a plurality of reference profiles; selecting from the plurality of reference profiles the reference profile to which the patient profile data most closely fits, in order to obtain a prediction of the psychological condition of the patient; assigning a treatment protocol to the patient based on the prediction of the psychological condition of the patient; wherein the plurality of reference profiles are determined by modelling a reference dataset comprising patient profile data relating to each of a plurality of other patients.

Abstract: The present invention relates generally to electronic smoking devices and in particular electronic cigarettes. A mouthpiece for an electronic smoking device has an elongated housing having ports at opposite ends; a central passage formed as a hollow channel through the housing in communication with the ports, contact terminals for connecting to a battery of the electronic smoking device and conductive elements connected to the contact terminals, the conductive elements being configured for connecting, to the battery, an tempering element for tempering an aerosol produced by the electronic smoking device. Using the tempering element, aerosol passing through the central passage can be tempered and loss of aerosol due to condensation is reduced.

Abstract: The present invention relates generally to electronic smoking devices and in particular electronic cigarettes. A mouthpiece for an electronic smoking device has an elongated housing having ports at opposite ends; a central passage formed as a hollow channel through the housing in communication with the ports, contact terminals for connecting to a battery of the electronic smoking device and conductive elements connected to the contact terminals, the conductive elements being configured for connecting, to the battery, an tempering element for tempering an aerosol produced by the electronic smoking device. Using the tempering element, aerosol passing through the central passage can be tempered and loss of aerosol due to condensation is reduced.

Abstract: Filter elements for gaseous fluid (e.g., air) filtration for wafer processing systems. The filter elements have a pleat ratio of no greater than 7, where the pleat ratio is the number of pleats per mean diameter of the filter. By having a pleat ratio no greater than 7, and in some implementations also greater than 5, the filter is optimized for wafer processing systems and methods. This pleat ratio optimizes the spacing between pleats, thus balancing filtration media area against effective area, such as what might be lost due to contaminant bridging.

Abstract: Filter elements for gaseous fluid (e.g., air) filtration for wafer processing systems. The filter elements have a pleat ratio of no greater than 7, where the pleat ratio is the number of pleats per mean diameter of the filter. By having a pleat ratio no greater than 7, and in some implementations also greater than 5, the filter is optimized for wafer processing systems and methods. This pleat ratio optimizes the spacing between pleats, thus balancing filtration media area against effective area, such as what might be lost due to contaminant bridging.